Fortrea Holdings (FTRE) Asset Writedowns and Impairment (2023 - 2026)
Fortrea Holdings (FTRE) reported Asset Writedowns and Impairment of $3.0 million for Q1 2026, down 33.33% on a YoY basis from $4.5 million in Q1 2025, and down 99.62% quarter-over-quarter from $797.9 million in Q3 2025.
Fortrea Holdings (FTRE) Asset Writedowns and Impairment (2023 - 2026) Analysis & Trends
Fortrea Holdings has reported Asset Writedowns and Impairment for 4 years, with the latest figure at $3.0 million in Q1 2026.
- For the quarter ending Q1 2026, Asset Writedowns and Impairment fell 33.33% year-over-year to $3.0 million; the trailing twelve-month figure through Mar 2026 stood at $796.4 million (up 29396.3% YoY), and the FY2025 full-year result was $797.9 million, up 3494.14% from the prior year.
- Asset Writedowns and Impairment for Q1 2026 stood at $3.0 million, down from $797.9 million in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $797.9 million in Q3 2025, with the low at -$31.4 million in Q3 2024.
- Historically, Asset Writedowns and Impairment has averaged $92.9 million across 4 years, with a median of $12.2 million in 2024.
- The largest YoY upside for Asset Writedowns and Impairment was 2641.08% in 2025 against a maximum downside of 136.89% in 2025.
- Fortrea Holdings' Asset Writedowns and Impairment stood at $13.4 million in 2023, then increased by 29.85% to $17.4 million in 2024, then soared by 4485.63% to $797.9 million in 2025, then tumbled by 99.62% to $3.0 million in 2026.
- The last three Asset Writedowns and Impairment figures came in at $3.0 million (Q1 2026), $797.9 million (Q3 2025), and -$4.5 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Fortrea Holdings | 1.43 Bn | 1.28 Bn | 123.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.00 Mn |
| Mar 31, 2026 | 3.00 Mn |
| Sep 30, 2025 | 797.90 Mn |
| Sep 30, 2025 | 797.90 Mn |
| Jun 30, 2025 | -4.50 Mn |
| Jun 30, 2025 | -4.50 Mn |
| Mar 31, 2025 | 4.50 Mn |
| Mar 31, 2025 | 4.50 Mn |
| Dec 31, 2024 | 17.40 Mn |
| Dec 31, 2024 | 17.40 Mn |
| Sep 30, 2024 | -31.40 Mn |
| Sep 30, 2024 | -31.40 Mn |
| Jun 30, 2024 | 12.20 Mn |
| Jun 30, 2024 | 12.20 Mn |
| Mar 31, 2024 | 24.00 Mn |
| Mar 31, 2024 | 24.00 Mn |
| Dec 31, 2023 | 13.40 Mn |
| Dec 31, 2023 | 13.40 Mn |